Log In
BCIQ
Print this Print this
 

AAT-Fc

  Manage Alerts
Collapse Summary General Information
Company Inhibrx LLC
DescriptionRecombinant alpha-1 antitrypsin (AAT; A1AT; SERPINA1) IgG Fc fusion protein
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAlpha-antitrypsin (AAT) deficiency
Indication DetailsTreat alpha-antitrypsin (AAT) deficiency
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/17/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today